Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – Time to Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.23 and traded as low as $3.27. Cryo-Cell International shares last traded at $3.41, with a volume of 5,548 shares traded.

Analyst Ratings Changes

Separately, Maxim Group downgraded shares of Cryo-Cell International from a “buy” rating to a “hold” rating in a research report on Monday, October 20th. One analyst has rated the stock with a Hold rating, According to MarketBeat, Cryo-Cell International presently has an average rating of “Hold” and a consensus price target of $8.50.

Cryo-Cell International Stock Performance

The stock has a market capitalization of $27.48 million, a price-to-earnings ratio of -48.71 and a beta of 0.59. The business’s 50 day simple moving average is $3.63 and its 200-day simple moving average is $4.23.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its quarterly earnings data on Wednesday, October 15th. The company reported $0.09 earnings per share (EPS) for the quarter. The business had revenue of $7.83 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is currently owned by institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.